Alzheimer’s disease (AD) represents one of the most challenging disorders, and despite having been widely studied since its first identification, resolutive treatments are still far out of reach. The current knowledge of this progressive, incurable disease involves many aspects of its pathology, even those not closely related to the main hallmarks of AD, Amyloid-beta (A) and Tau [1]. However, despite the emergence a new, complex perspective of AD as a multifactorial disease, the role of A and Tau remains central. Looking at the current pipeline of AD drug development, great efforts are being made to move from symptomatic to disease-modifying treatments
Amyloid-Beta and Alzheimer's Disease: Molecular Updates from Physiology to Pathology
Maria Laura GiuffridaPrimo
2023
Abstract
Alzheimer’s disease (AD) represents one of the most challenging disorders, and despite having been widely studied since its first identification, resolutive treatments are still far out of reach. The current knowledge of this progressive, incurable disease involves many aspects of its pathology, even those not closely related to the main hallmarks of AD, Amyloid-beta (A) and Tau [1]. However, despite the emergence a new, complex perspective of AD as a multifactorial disease, the role of A and Tau remains central. Looking at the current pipeline of AD drug development, great efforts are being made to move from symptomatic to disease-modifying treatmentsI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
